Fulcrum Therapeutics slashes 85% of workforce, approves restructuring after lead drug failure
FULC sits 18% above its 52-week low of $2.83 on elevated volume (3.1× avg).
Summary
Fulcrum Therapeutics has approved a major restructuring plan, including an 85% reduction in its workforce, cutting from 57 to 9 employees. This drastic measure follows the recent discontinuation of their lead sickle cell disease drug, pociredir, due to FDA safety concerns, which was reported earlier this week. The company expects to incur approximately $4.2 million in restructuring charges in Q2 2026. This significant operational contraction indicates a severe impact on the company's future and a fundamental shift in its strategic direction after the failure of its primary clinical asset. The company is currently undergoing a strategic review to determine its path forward.
At the time of this announcement, FULC was trading at $3.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $224.6M. The 52-week trading range was $2.83 to $15.74. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.